Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California (NASDAQ:PACB) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Is PACB or HBIO more profitable?

Harvard Bioscience has a net margin of -14.57% compared to Pacific Biosciences of California's net margin of -200.40%. Harvard Bioscience's return on equity of -4.64% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-200.40%	-42.89%	-14.77%
Harvard Bioscience	-14.57%	-4.64%	-2.40%

Does the MarketBeat Community favor PACB or HBIO?

Pacific Biosciences of California received 84 more outperform votes than Harvard Bioscience when rated by MarketBeat users. However, 71.51% of users gave Harvard Bioscience an outperform vote while only 66.42% of users gave Pacific Biosciences of California an outperform vote.

Company	Underperform	Outperform
Pacific Biosciences of California	Outperform Votes 453 66.42%	Underperform Votes 229 33.58%
Harvard Bioscience	Outperform Votes 369 71.51%	Underperform Votes 147 28.49%

Which has more risk & volatility, PACB or HBIO?

Pacific Biosciences of California has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in PACB or HBIO?

80.9% of Harvard Bioscience shares are owned by institutional investors. 2.4% of Pacific Biosciences of California shares are owned by company insiders. Comparatively, 9.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has higher valuation & earnings, PACB or HBIO?

Harvard Bioscience has lower revenue, but higher earnings than Pacific Biosciences of California. Harvard Bioscience is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$154.01M	2.23	-$308.65M	-$1.64	-0.70
Harvard Bioscience	$94.14M	0.16	-$3.41M	-$0.29	-1.20

Do analysts rate PACB or HBIO?

Pacific Biosciences of California currently has a consensus target price of $2.45, indicating a potential upside of 113.97%. Harvard Bioscience has a consensus target price of $4.50, indicating a potential upside of 1,189.40%. Given Harvard Bioscience's higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	0 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Harvard Bioscience	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media prefer PACB or HBIO?

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Harvard Bioscience. MarketBeat recorded 5 mentions for Pacific Biosciences of California and 4 mentions for Harvard Bioscience. Pacific Biosciences of California's average media sentiment score of 0.93 beat Harvard Bioscience's score of -0.08 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Harvard Bioscience beats Pacific Biosciences of California on 9 of the 17 factors compared between the two stocks.